Fjarde AP Fonden Fourth Swedish National Pension Fund Boosts Stock Holdings in Boston Scientific Corporation $BSX

Fjarde AP Fonden Fourth Swedish National Pension Fund raised its holdings in Boston Scientific Corporation (NYSE:BSX) by 24.0% in the 2nd quarter, Holdings Channel.com reports. The firm owned 287,958 shares of the medical equipment provider’s stock after acquiring an additional 55,800 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Boston Scientific were worth $30,930,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently modified their holdings of the company. 1248 Management LLC purchased a new position in shares of Boston Scientific in the first quarter worth about $26,000. Y.D. More Investments Ltd purchased a new position in Boston Scientific during the first quarter valued at approximately $27,000. Sound Income Strategies LLC grew its stake in Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 120 shares in the last quarter. Princeton Global Asset Management LLC purchased a new position in Boston Scientific during the second quarter valued at approximately $32,000. Finally, Oliver Lagore Vanvalin Investment Group purchased a new position in Boston Scientific during the second quarter valued at approximately $37,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on BSX. Wells Fargo & Company boosted their price objective on shares of Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. The Goldman Sachs Group reaffirmed a “buy” rating and set a $124.00 price objective on shares of Boston Scientific in a research note on Wednesday, October 22nd. Jefferies Financial Group reaffirmed a “hold” rating on shares of Boston Scientific in a research note on Monday, July 21st. Evercore ISI reiterated an “outperform” rating on shares of Boston Scientific in a research report on Wednesday, October 22nd. Finally, BTIG Research reiterated a “buy” rating and set a $132.00 target price on shares of Boston Scientific in a research report on Wednesday, October 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, Boston Scientific currently has a consensus rating of “Buy” and an average target price of $123.77.

Boston Scientific Trading Up 1.3%

Shares of Boston Scientific stock opened at $102.43 on Tuesday. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50. The firm has a market cap of $151.77 billion, a PE ratio of 54.77, a PEG ratio of 2.04 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company has a 50 day simple moving average of $101.13 and a two-hundred day simple moving average of $102.16.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The firm had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The business’s quarterly revenue was up 20.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,469,268. The trade was a 42.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $17,561,336.74. The trade was a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 167,313 shares of company stock valued at $17,237,959. Company insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.